 WES MOORE, Governor  Ch. 962  
 
– 1 – Chapter 962  
(House Bill 1056 ) 
 
AN ACT concerning  
 
State Board of Pharmacy – Prohibition on Discrimination Against 340B Drug 
Distribution  
 
FOR the purpose of prohibiting a 340B manufacturer , wholesale drug distributor, or  
third –party logistics provider, or an agent or affiliate of a 340B manufacturer, 
wholesale drug distributor, or third –party logistics provider,  from taking certain 
direct or indirect  actions to limit or restric t the acquisition or delivery of a 340B drug; 
making a violation of this Act an unfair, abusive, or deceptive trade practice within 
the meaning of the Consumer Protection Act; requiring the Maryland Prescription 
Drug Affordability Board to conduct a study of the 340B Program;  and generally 
relating to 340B drugs.  
 
BY repealing and reenacting, with amendments,  
 Article – Commercial Law  
Section 13 –301(14)(xl)  
 Annotated Code of Maryland  
 (2013 Replacement Volume and 2023 Supplement)  
 
BY repealing and reenacting, without amendments,  
 Article – Commercial Law  
Section 13 –301(14)(xli)  
 Annotated Code of Maryland  
 (2013 Replacement Volume and 2023 Supplement)  
 
BY adding to  
 Article – Commercial Law  
Section 13 –301(14)(xlii)  
 Annotated Code of Maryland  
 (2013  Replacement Volume and 2023 Supplement)  
 
BY repealing and reenacting, without amendments,  
 Article – Health Occupations  
Section 12 –101(a) and (d)  
 Annotated Code of Maryland  
 (2021 Replacement Volume and 2023 Supplement)  
 
BY adding to  
 Article – Health Oc cupations  
Section 12 –6C–09.1 
 Annotated Code of Maryland  
 (2021 Replacement Volume and 2023 Supplement)  
Ch. 962  2024 LAWS OF MARYLAND   
 
– 2 –  
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 
That the Laws of Maryland read as follows:  
 
Article – Commercial Law  
 
13–301. 
 
 Unfair, abusive, or deceptive trade practices include any:  
 
  (14) Violation of a provision of:  
 
   (xl) Title 14, Subtitle 13 of the Public Safety Article; [or] 
 
   (xli) Title 14, Subtitle 45 of this article; or  
 
   (XLII) SECTION 12–6C–09.1  OF THE HEALTH OCCUPATIONS 
ARTICLE ; OR 
 
Article – Health Occupations  
 
12–101. 
 
 (a) In this title the following words have the meanings indicated.  
 
 (d) “Board” means the State Board of Pharmacy.  
 
12–6C–09.1.  
 
 (A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE MEANINGS 
INDICATED .  
 
  (2) “COVERED ENTITY ” HAS THE MEANING STAT ED IN 42 U.S.C.  § 
256B(A)(4).   
 
  (3) “PACKAGE ” HAS THE MEANING STAT ED IN 21 U.S.C.  § 
360EEE(11).  
 
  (4) (I) “340B  DRUG” MEANS A DRUG THAT : 
 
    1. IS A COVERED OUTPATIE NT DRUG UNDER 42 U.S.C.  § 
256B; 
 
    2. HAS BEEN SUBJECT TO A N OFFER FOR REDUCED 
PRICES BY A 340B  MANUFACTURER UNDER 42 U.S.C.  § 256B(A)(1);  AND 
 WES MOORE, Governor  Ch. 962  
 
– 3 –  
    3. IS PURCHASED BY A COV ERED ENTITY .  
 
   (II) “340B  DRUG” INCLUDES A DRUG THAT  WOU LD HAVE BEEN 
PURCHASED BUT FOR TH E LIMITATION UNDER S UBSECTION (D) (C) OF THIS 
SECTION .  
 
  (5) “340B  MANUFACTURER ” MEANS A MANUFACTURER , AS DEFINED 
IN 42 U.S.C.  § 1396 R–8(K)(5),  OF COVERED OUTPATIEN T DRUGS THAT HAS SIG NED 
A PHARMACEUTICAL PRI CING AGREEMENT UNDER  42 U.S.C.  § 256B(A)(1).   
 
 (B) THIS SECTION APPLIES TO: 
 
  (1) A 340B  MANUFACTURER ; 
 
  (2) A WHOLESALE DRUG DISTR IBUTOR ; 
 
  (3) A THIRD–PARTY LOGISTICS PROV IDER ; AND  
 
  (4) AN AGENT OR AFFILIATE  OF A 340B  MANUFACTURER , 
WHOLESALE DRUG DISTR IBUTOR , OR THIRD –PARTY LOGISTICS PROV IDER .  
 
 (C) THIS SECTION MAY NOT BE CONSTRUED TO BE : 
 
  (1) LESS RESTRICTIVE THAN ANY  FEDERAL LAW THAT IS APPLICABLE 
TO A PERSON REGULATE D BY THIS SECTION ; OR 
 
  (2) IN CONFLICT WITH APPL ICABLE FEDERAL AND STATE LAWS AND 
REGULATIONS . 
 
 (D) (C) (1) EXCEPT AS PROVIDED IN  PARAGRAPH (2) OF THIS 
SUBSECTION , AN ENTITY SUBJECT  TO THIS SECTION  A 340B  MANUFACTURER  MAY 
NOT DIRECTLY OR INDI RECTLY DENY , RESTRICT , PROHIBIT , DISCRIMINATE 
AGAINST , OR OTHERWISE LIMIT T HE ACQUISITION OF A 340B  DRUG BY , OR 
DELIVERY OF A 340B  DRUG TO , A PHARMACY THAT IS U NDER CONTRACT WITH O R 
OTHERWISE AUT HORIZED BY A COVERED  ENTITY TO RECEIVE 340B  DRUGS ON 
BEHALF OF THE COVERE D ENTITY UNLESS THE  RECEIPT OF 340B  DRUGS IS 
PROHIBITED BY THE U.S.  DEPARTMENT OF HEALTH AND HUMAN SERVICES .  
 
  (2) AN ENTITY SUBJECT TO THIS SECTION  A 340B  MANUFACTURER  
MAY LIMIT TH E DISTRIBUTION OF A 340B  DRUG IF THE LIMITATI ON IS REQUIRED 
UNDER 21 U.S.C.  § 355–1.  
 
Ch. 962  2024 LAWS OF MARYLAND   
 
– 4 –  (E) (D) (1) (I) A VIOLATION OF SUBSECT ION (D) (C) OF THIS  
SECTION : 
 
   (I) 1. SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , IS 
AN UNFAIR , ABUSIVE , OR DECEPTIVE TRADE PRACTICE WITHIN THE MEANING OF 
TITLE 13 OF THE COMMERCIAL LAW ARTICLE AND IS SUBJEC T TO THE 
ENFORCEMENT AND PENA LTY PROVISIONS CONTA INED IN TITLE 13 OF THE 
COMMERCIAL LAW ARTICLE ; AND  
 
   (II) 2. A. SHALL  IF THE ALLEGED VIOLAT ION WAS 
COMMITTED BY A PERSO N THAT IS LICENSED OR PERMITTED BY THE BOARD , SHALL  
BE JOINTLY OR SEPARATEL Y INVESTIGATED BY  THE BOARD OR THE CONSUMER 
PROTECTION DIVISION OF THE OFFICE OF THE ATTORNEY GENERAL ; OR 
 
    B. IF THE ALLEGED VIOLAT ION WAS COMMITTED BY  A 
PERSON THAT IS NOT L ICENS ED OR PERMITTED BY T HE BOARD , SHALL BE 
INVESTIGATED BY THE CONSUMER PROTECTION DIVISION OF THE OFFICE OF THE 
ATTORNEY GENERAL . 
 
   (II) AS PART OF AN INVESTI GATION CONDUCTED UND ER 
SUB PARAGRAPH (1)(I)2 OF THIS PARAGRAPH , THE BOARD OR THE CONSUMER 
PROTECTION  DIVISION OF THE OFFICE OF THE ATTORNEY GENERAL MAY 
INVESTIGATE AN AFFIL IATE OR A CONTRACTOR  OF THE 340B  MANUFACTURER , 
INCLUDING A WHOLESAL ER OR THIRD –PARTY LOGISTICS PROV IDER .  
 
  (2) (I) IN ADDITION TO THE PE NALTIES UNDER TITLE 13 OF THE 
COMMERCIAL LAW ARTICLE , A CIVIL FINE MAY BE ASSESSED IN THE AMOU NT OF 
$50,000  $5,000  PER VIOLATION OF SUB SECTION (D) (C) OF THIS SECTION .  
 
   (II) A VIOLATION OF THIS SE CTION DOES NOT CREAT E A 
PRIVATE RIGHT OF ACT ION UNDER § 13–408 OF THE COMMERCIAL LAW ARTICLE .  
 
  (3) IF A VIOLATION OF SUB SECTION (D) (C) OF THIS SECTION IS 
COMMITTED BY A PERSO N LICENSED OR PERMIT TED BY THE BOARD , THE BOARD 
MAY IMPOSE DISCIPLIN E, SUSPENSION , OR REVOCATION OF THE  PERSON ’S LICENSE 
OR PERMIT . 
 
  (4) EACH PACKAGE OF 340B  DRUGS SUBJECT TO A V IOLATION OF 
SUBSECTION (D) (C) OF THIS SECTION SHAL L CONSTITUTE A SEPAR ATE VIOLATION .  
 
 SECTION 2. AND BE IT FURTHER ENACTED, That:  
 
 WES MOORE, Governor  Ch. 962  
 
– 5 –  (a) The Maryland Prescription Drug Affordability Board, in consultation with the 
Maryland Department of Health:  
 
  (1) shall conduct a study on:  
 
   (i) the current implementation and scope of the 340B Program in 
the State;  
 
   (ii) the implementation and impact of the implementation of Section 
1 of this Act; and  
 
   (iii) the finances of the Program in the State, includin g how covered 
entities reinvest savings realized from the Program; and  
 
  (2) may require covered entities and 340B manufacturers to report 
information as necessary to complete the study.  
 
 (b) On or before July 1, 2026, the Maryland Prescription Drug Affo rdability Board 
shall report its findings and recommendations from the study to the Senate Finance 
Committee and the House Health and Government Operations Committee, in accordance 
with § 2 –1257 of the State Government Article.  
 
 SECTION 2. 3. AND BE IT F URTHER ENACTED, That this Act shall take effect 
July 1, 2024.  
 
Approved by the Governor, May 16, 2024.  